ACP Bets Big on Radiology Roll-Up with Heritage Imaging Platform

ACP, the Nashville-based private equity firm with $6 billion under management, has acquired Heritage Imaging to serve as its first platform investment in the outpatient diagnostic imaging sector. The deal, announced Wednesday, positions ACP to pursue an aggressive buy-and-build strategy across one of healthcare's most fragmented service categories — a market where independent radiology practices still dominate despite years of consolidation talk.

Heritage Imaging operates six imaging centers across Oregon and Washington, offering MRI, CT, ultrasound, X-ray, and nuclear medicine services. The company has built what ACP describes as a "patient-first model" — shorthand for convenient scheduling, transparent pricing, and faster turnaround times than hospital-based competitors. That operational playbook is what ACP intends to replicate.

Terms weren't disclosed, but sources familiar with outpatient imaging valuations estimate the transaction in the $100-150 million range based on Heritage's geographic footprint and service mix. ACP declined to comment on pricing. What matters more than the entry price is the addressable market: outpatient diagnostic imaging generates roughly $14 billion annually in the U.S., and independent operators still control the majority of it.

ACP Managing Director Bill Hall framed the thesis plainly. "The outpatient diagnostic imaging market remains highly fragmented, with significant opportunities to scale high-quality, independent providers," he said in the announcement. Translation: there are hundreds of one- and two-location radiology practices that could be folded into a larger platform if the economics and culture align.

Private equity's interest in radiology isn't new — firms have been circling the sector for a decade. But previous consolidation waves focused on physician practice management or hospital partnerships, often with mixed results. What's different this time is the shift in patient preference and payer pressure toward lower-cost outpatient settings.

Hospital-based imaging is expensive. An MRI at a hospital outpatient department can run 50-100% more than the same scan at an independent center, thanks to facility fees and institutional overhead. Insurers know this. Patients — especially those on high-deductible plans — feel it. That cost differential is driving volume toward freestanding centers, creating the margin profile PE firms need to justify platform investments.

The technology is also stabilizing. Imaging equipment is capital-intensive, but the machines last longer now, and financing is cheap relative to historical norms. A well-run imaging center can generate mid-to-high teens EBITDA margins if it hits utilization targets. Scale those margins across 20-30 locations, layer in procurement savings and shared back-office infrastructure, and you've got a roll-up model that works on paper.

ACP's timing also reflects broader demographic tailwinds. An aging population means more diagnostic imaging — Medicare beneficiaries are heavy users of MRI and CT scans. And while telehealth grabbed headlines during the pandemic, diagnostic imaging never went virtual. You can't Zoom an MRI. The service is stubbornly in-person, which insulates it from some of the disruption risk that's hammered other healthcare verticals.

Heritage Imaging has been around for over two decades, building a reputation in the Pacific Northwest for above-average patient experience and radiologist quality. The company employs board-certified radiologists who subspecialize — meaning a musculoskeletal scan gets read by someone who focuses on MSK, not a generalist. That clinical depth matters when you're trying to differentiate in a commoditized market.

The six-center footprint is concentrated but not overlapping — each location serves a distinct catchment area, mostly in suburban corridors where patients prefer convenience over proximity to a hospital. Heritage's facilities average around 3,500-4,000 square feet, large enough to house multiple modalities but small enough to keep real estate costs manageable.

Pricing transparency is part of Heritage's pitch. Patients can see upfront costs before booking, and the company accepts most major insurance plans while also offering competitive self-pay rates. That model appeals to the growing share of Americans on high-deductible plans who are effectively paying out-of-pocket until they hit their annual limit.

Heritage also invested in patient scheduling technology that reduces wait times — a chronic pain point in hospital-based imaging, where emergency cases often bump scheduled scans. Outpatient centers don't have that conflict. You book a Tuesday morning MRI, you get your Tuesday morning MRI. For patients juggling work schedules, that predictability is worth something.

The cost gap isn't academic. For a patient with a $3,000 deductible, choosing an outpatient MRI over a hospital scan can mean the difference between paying $600 out-of-pocket versus $1,500. Multiply that across thousands of scans annually, and the savings add up for insurers and patients alike.

Radiology is a referral-driven business. Primary care doctors and specialists send patients where they trust the reads. Heritage's radiologists maintain ACR accreditation and participate in peer review — table stakes in the industry, but not universally practiced among smaller independents. ACP is betting that clinical credibility, combined with operational efficiency, creates a defensible position against both hospital systems and other consolidators.

ACP isn't buying Heritage to hold six centers. This is a platform play — which means the firm is hunting for tuck-in acquisitions across the West Coast and potentially beyond. The target profile is clear: independent imaging centers with 1-3 locations, solid payer contracts, accredited radiologists, and owner-operators looking for liquidity or succession solutions.

The radiology sector is packed with baby boomer owners who've run their practices for 20-30 years and are ready to exit. Many lack succession plans because their kids didn't go into medicine, and selling to a hospital often means losing autonomy. PE-backed platforms offer a third option: liquidity today, continued involvement if desired, and access to the capital needed to upgrade equipment or expand.

ACP will likely move fast. In fragmented healthcare roll-ups, speed matters — once one platform gets momentum, others follow, and purchase price multiples inflate. Expect ACP to close 3-5 add-ons within the first 12-18 months. The firm has deep experience in healthcare services (previous portfolio companies include surgical hospitals and specialty pharmacy assets), so it knows the diligence process and regulatory hurdles.

Geographic density will be key. ACP will probably prioritize Washington, Oregon, and Northern California initially — markets where Heritage already has brand recognition and where there's a critical mass of independent centers to acquire. Building out a regional network before jumping to a new geography makes operational integration cleaner and allows the platform to negotiate better rates with regional insurers.

The firm will also need to decide whether to pursue a physician practice model or a management services organization structure. Some states restrict corporate practice of medicine, which complicates ownership structures. ACP likely structured the Heritage deal as an MSO, allowing the radiologists to retain ownership of the clinical entity while ACP controls the operational and real estate side.

Roll-ups always sound cleaner on paper than they prove in practice. Radiology is no exception. Integrating IT systems is a nightmare — every practice has its own RIS/PACS setup, and migrating patient records without disrupting workflow takes months. Then there's payer contracting: Heritage's insurance rates won't automatically transfer to acquired centers, so each deal requires renegotiation or at least contract assignment.

Culture clashes are real too. Independent radiologists are used to autonomy. The moment they start getting directives from a corporate office about scheduling protocols or reporting templates, some will bristle. ACP will need to walk a fine line — capturing operational efficiencies without alienating the physicians who are the product.

ACP isn't entering an empty field. RadNet, the largest independent imaging operator in the U.S., runs over 350 centers and has been gobbling up competitors for years. SimonMed Imaging, backed by Audax Private Equity, operates over 200 locations across the Southwest and has been expanding aggressively. Both have scale advantages ACP doesn't — yet.

But the market is big enough for multiple winners. RadNet and SimonMed are concentrated in specific regions (RadNet in California and the Northeast; SimonMed in Arizona, Nevada, and New Mexico). The Pacific Northwest has been relatively overlooked by national consolidators, which gives Heritage a head start in a defined geography.

Hospital systems are the other competitor, though their economics are different. Hospitals want imaging patients for the downstream revenue — the MRI is the gateway to the orthopedic surgery or the oncology referral. They'll often lose money on imaging if it drives higher-margin procedures. Independent centers can't play that game, so they have to win on cost and convenience alone.

There's also the question of payer strategy. Some insurers are building their own imaging networks or steering patients toward mega-platforms like RadNet to extract volume discounts. If ACP can't scale Heritage quickly enough to become a preferred partner for major payers, it risks getting shut out of network contracts — which would be fatal.

AI-assisted radiology reads are no longer hypothetical. Multiple FDA-cleared algorithms now flag potential abnormalities in imaging studies, reducing read times and catching findings that human radiologists might miss. The technology is being adopted fastest by large platforms that can afford enterprise licensing deals. If ACP wants Heritage to compete on clinical quality long-term, it'll need to invest in AI tools — another capital call.

The flip side: AI could eventually commoditize radiology interpretation, compressing the value that subspecialized radiologists provide. If an algorithm can read a musculoskeletal MRI as accurately as a fellowship-trained radiologist, what's the moat? ACP is betting that won't happen fast enough to derail the roll-up thesis, but it's a risk worth watching.

ACP's entry signals that PE firms see a viable consolidation window in outpatient imaging — one that may not stay open indefinitely. If several platforms raise capital and start competing for the same acquisition targets, multiples will rise and returns will compress. The firms that move fastest and integrate best will win. The ones that overpay or botch post-merger integration will bleed capital.

For independent imaging center owners, the message is clear: expect more inbound calls. PE-backed platforms need deal flow, and they'll pay for quality assets. Owners who've been thinking about selling now have leverage. Those who wait may find the landscape more crowded and the terms less favorable.

For patients and payers, consolidation is a mixed bag. Larger platforms can negotiate better pricing on equipment and supplies, which could flow through to lower costs. But they also have more market power to resist rate cuts from insurers. Whether consolidation leads to lower prices depends on how competitive the post-consolidation market remains — and how aggressively regulators scrutinize deals.

Hospital systems should be paying attention too. If PE-backed imaging platforms scale successfully, they'll siphon profitable outpatient volume away from hospital radiology departments. That revenue loss matters, especially for community hospitals that rely on imaging margins to subsidize less profitable service lines.

This isn't ACP's first rodeo in healthcare services. The firm has a 30-year track record of backing middle-market companies in healthcare, business services, and industrial sectors. Previous healthcare investments include surgical facilities, home health agencies, and specialty distribution businesses — all sectors where fragmentation created roll-up opportunities.

ACP's typical hold period is 4-6 years. That suggests Heritage will likely be exited around 2029-2031, either through a sale to a larger strategic (like RadNet or a hospital system) or a secondary buyout to another PE firm. The playbook is predictable: acquire the platform, bolt on 10-20 tuck-ins, professionalize operations, hit $200-300 million in revenue, then sell.

The competitive set shows how much runway remains. RadNet took decades to reach 350 centers. SimonMed got to 200 in about 15 years with aggressive M&A. ACP is starting at six but has the capital and experience to compress that timeline — if execution holds.

One factor working in ACP's favor: debt is still relatively accessible for healthcare services platforms with predictable cash flow. Even with rates higher than the 2020-2021 lows, quality imaging businesses can get leverage at reasonable terms. That allows ACP to fund acquisitions without burning too much equity, preserving returns for limited partners.

The next 12 months will tell the story. If ACP closes 3-5 add-ons and Heritage's organic growth stays strong, the thesis is working. If integration proves messier than expected or if regional competitors (hospital systems or other consolidators) respond aggressively, the path gets harder.

Keep an eye on payer dynamics. If major insurers in the Pacific Northwest shift toward narrow imaging networks or capitated arrangements, Heritage's reimbursement could get squeezed. ACP will need to prove it can grow patient volume and diversify payer mix quickly.

Watch for secondary platforms emerging in the same geography. If another PE firm plants a flag in Oregon or Washington with a competing imaging roll-up, acquisition multiples will spike and the race will be on. First-mover advantage matters, but only if you move fast.

And pay attention to regulatory scrutiny. The FTC has been more aggressive about challenging healthcare consolidation, particularly in markets where a deal might create or enhance monopoly power. ACP will need to be thoughtful about which acquisitions to pursue in overlapping geographies to avoid triggering a second request.